COMP <GO>
CDRE vs LLY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Cadre Holdings Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CDRE 4
— LLY 8
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: CDRE
LAST: $31.10 (+3.81%) • MKT CAP: $1.33B
dividend-safety
1.16%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.33T
dividend-safety
0.49%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CDRE VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CDRE | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 42.50% | 83.64% | -41.14 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.00% | 32.36% | -21.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 20.5x | 36.4x | -15.92 | CDRE | /valuation <GO> |
| Free Cash Flow Yield | 4.27% | 2.30% | +1.97 | CDRE | /fcf-yield <GO> |
| Operating Margin | 11.00% | 40.21% | -29.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 7.20% | 31.90% | -24.70 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 7.50% | 45.51% | -38.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 1.16% | 0.49% | +0.67 | CDRE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.32 | 9.29 | -5.97 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.0 | 77.9 | -12.85 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 28.1x | 30.6x | -2.52 | CDRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.33B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CDRE REV | LLY REV | CDRE GROSS % | LLY GROSS % | CDRE FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $610.3M | $65.18B | 42.5% | 83.0% | $56.8M | $16.81B |
| FY 2024 | $567.6M | $45.04B | 41.1% | 81.3% | $26.1M | $8.82B |
| FY 2023 | $482.5M | $34.12B | — | 79.3% | $73.2M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CDRE // BETA —
LLY // BETA 0.51